Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;30(2):221-235.
doi: 10.1038/s41417-022-00555-1. Epub 2022 Nov 11.

EZH1/2 as targets for cancer therapy

Ran An  1 , Yu-Qing Li  1 , Yue-Ling Lin  1 , Fang Xu  2 , Man-Mei Li  2 , Zhong Liu  3
Affiliations
Review

EZH1/2 as targets for cancer therapy

Ran An et al. Cancer Gene Ther. 2023 Feb.

Abstract

The enhancer of zeste homolog 2 (EZH2) and its highly related homolog EZH1 are considered to be epigenetic silencing factors, and they play key roles in the growth and differentiation of cells as the core components of polycomb repressive complex 2 (PRC2). EZH1 and EZH2 are known to have a role in human malignancies, and alterations in these two genes have been implicated in transformation of human malignancies. Inhibition of EZH1/2 has been shown to result in tumor regression in humans and has been studied and evaluated in the preclinical setting and in multiple clinical trials at various levels. Our work thus contributes to the understanding of the relationship between regulatory molecules associated with EZH1/2 proteins and tumor progression, and may provide new insights for mechanism-based EZH1/2-targeted therapy in tumors.

PubMed Disclaimer

References

    1. Lee CH, Yu JR, Kumar S, Jin Y, LeRoy G, Bhanu N, et al. Allosteric activation dictates PRC2 activity independent of its recruitment to chromatin. Mol Cell. 2018;70:422–34.e6. - DOI
    1. Chen S, Jiao L, Shubbar M, Yang X, Liu X. Unique Structural platforms of SUZ12 dictate distinct classes of PRC2 for chromatin binding. Mol Cell. 2018;69:840–52.e5–. - DOI
    1. Chammas P, Mocavini I, Di Croce L. Engaging chromatin: PRC2 structure meets function. Br J cancer. 2020;122:315–28. - DOI
    1. Zhao Y, Guan YY, Zhao F, Yu T, Zhang SJ, Zhang YZ, et al. Recent strategies targeting embryonic ectoderm development (EED) for cancer therapy: allosteric inhibitors, PPI inhibitors, and PROTACs. Eur J Medicinal Chem. 2022;231:114144. - DOI
    1. Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, et al. Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature. 2021;589:299–305. - DOI

Publication types

MeSH terms

Substances

LinkOut - more resources